Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.
Here, we will give a short insight into our published results: Original publications
Eingeschlossene Patienten: 23.123 (Stand 01. November 2024) | |
---|---|
Amgevita® (Adalimumab) | 232 |
Benepali® (Etanercept) | 1231 |
Cimzia® (Certolizumab) | 1038 |
Enbrel® (Etanercept) | 2872 |
Erelzi® (Etanercept) | 566 |
Flixabi® (Infliximab) | 10 |
Hukyndra® (Adalimumab) | 8 |
Hulio® (Adalimumab) | 258 |
Humira® (Adalimumab) | 2910 |
Hyrimoz® (Adalimumab) | 239 |
Idacio® (Adalimumab) | 66 |
Imraldi® (Adalimumab) | 230 |
Inflectra™ (Infliximab) | 17 |
Jyseleca® (Filgotinib) | 153 |
Kevzara® (Sarilumab) | 223 |
Kineret® (Anakinra) | 89 |
MabThera® (Rituximab) | 1459 |
Nepexto® (Etanercept) | 90 |
Olumiant® (Baricitinib) | 545 |
Orencia® (Abatacept) | 990 |
Remicade® (Infliximab) | 762 |
Remsima® (Infliximab) | 25 |
Rinvoq® (Upadacitinib) | 311 |
Rixathon® (Rituximab) | 20 |
RoActemra® (Tocilizumab) | 1378 |
Ruxience® (Rituximab) | 1 |
Simponi® (Golimumab) | 473 |
Truxima® (Rituximab) | 2 |
Tyenne® (Tocilizumab) | 31 |
Xeljanz® (Tofacitinib) | 397 |
Yuflyma® (Adalimumab) | 46 |
Zessly® (Infliximab) | 2 |
Kontrollen | 6449 |